BMJ 2003;326:1358-1362 (21 June), doi:10.1136/bmj.326.7403.1358
Paper
Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis
Raymond S M Wong, haematologist1,
Alan Wu, medical and health officer1,
K F To, associate professor2,
Nelson Lee, medical and health officer1,
Christopher W K Lam, professor3,
C K Wong, associate professor3,
Paul K S Chan, associate professor4,
Margaret H L Ng, associate professor2,
L M Yu, statistician5,
David S Hui, associate professor1,
John S Tam, professor4,
Gregory Cheng, associate professor1,
Joseph J Y Sung, professor1
1 Department of Medicine and Therapeutics, Chinese University of Hong Kong,
Prince of Wales Hospital, Shatin, New Territories, Hong Kong Special
Administrative Region, China,
2 Department of Anatomical and Cellular Pathology, Chinese University of Hong
Kong,
3 Department of Chemical Pathology, Chinese University of Hong Kong,
4 Department of Microbiology, Chinese University of Hong Kong,
5 Centre for Clinical Trials and Epidemiological Research, Chinese University of
Hong Kong
Correspondence to: J J Y Sung
joesung{at}cuhk.edu.hk
Abstract
Objectives To evaluate the haematological findings of patients
with
severe acute respiratory syndrome (SARS).
Design Analysis of the demographic, clinical, and laboratory
characteristics of patients with SARS.
Setting Prince of Wales Hospital, Hong Kong.
Subjects All patients with a diagnosis of SARS between 11 March and
29 March 2003 who had no pre-existing haematological disorders.
Main outcome measures Clinical end points included the need for
intensive care and death. Univariate and multivariate analyses were performed
to examine factors associated with adverse outcome.
Results 64 male and 93 female patients were included in this study.
The most common findings included lymphopenia in 153 (98%) of the 157
patients, neutrophilia in 129 (82%), thrombocytopenia in 87 patients (55%),
followed by thrombocytosis in 77 (49%), and isolated prolonged activated
partial thromboplastin time in 96 patients (63%). The haemoglobin count
dropped by more than 20 g/l from baseline in 95 (61%) patients. Four patients
(2.5%) developed disseminated intravascular coagulation. Lymphopenia was shown
in haemato-lymphoid organs at postmortem examination. Multivariate analysis
showed that advanced age and a high concentration of lactate dehydrogenase at
presentation were independent predictors of an adverse outcome. Subsets of
peripheral blood lymphocytes were analysed in 31 patients. The counts of CD4
positive and CD8 positive T cells fell early in the course of illness. Low
counts of CD4 and CD8 cells at presentation were associated with adverse
outcomes.
Conclusions Abnormal haematological variables were common among
patients with SARS. Lymphopenia and the depletion of T lymphocyte subsets may
be associated with disease activity.
Introduction
An outbreak of severe acute respiratory syndrome (SARS) has
recently been
reported from Hong
Kong.
1 A novel
coronavirus
has been identified as the aetiological agent of the
syndrome.
2
3 Viral infection may
produce various haematological changes.
Early studies have shown that
lymphopenia and thrombocytopenia
are common among patients with
SARS.
1
4 This study summarises
the haematological findings in patients with SARS who were treated
at the
Prince of Wales Hospital, Hong Kong.
Methods
Study population
Our study included all consecutive patients who received a diagnosis
of
SARS and were treated at the Prince of Wales Hospital but
excluded patients
with a history of haematological disorders.
Based on the criteria for SARS
that have been established by
the US Centers for Disease Control and
Prevention (CDC), our
case definition was a fever (temperature > 38°C),
a
chest radiograph or a computed tomographic image of the thorax
showing
evidence of consolidation with or without respiratory
symptoms, and a history
of close contact with a person in whom
SARS had been diagnosed. The diagnosis
was confirmed by an
indirect immunofluorescence assay with fetal rhesus kidney
cells that were infected with coronavirus and fixed in acetone
to detect a
serological response to the
virus
3 or by a
positive
viral culture.
Laboratory studies
Initial haematological investigations included a complete blood count with
differential count and clotting profile (prothrombin time, activated partial
thromboplastin time, and international normalised ratio). We studied these
variables daily until a patient's fever had subsided for three days, then as
clinically indicated, and at follow up visits after discharge from hospital.
In some patients the chosen method was immunophenotyping with MultiTEST IMK
kit, using flow cytometry (FACSCalibur 4 color system, BD Biosciences,
California, United States) to obtain serial measurements of lymphocytes
subsets in peripheral blood. We conducted postmortem investigations in some
patients who died of SARS.
Data collection and analysis
We analysed the reported demographic, clinical, and laboratory
characteristics. Day 1 was defined as the day of onset of fever.
The clinical
composite end point was the need for care in an
intensive care unit, death, or
both. We used univariate analysis
to compare patients who reached the end
point and those who
did not, by using an unpaired Student's
t test,
2 test, or
Fisher's exact test, as appropriate. We then
performed multiple
logistic regression analysis, with stepwise analysis, to
identify
independent predictors of the end point after adjusting for
age and
concentration of lactate dehydrogenase at
presentation.
1 Only
baseline variables were used as factors for predicting
outcome, and those with
a P value of less than 0.20 by univariate
analysis were entered into the
model. A P value of less than
0.05 was considered to indicate statistical
significance. All
probabilities are two tailed. We used SPSS for Windows
(release
11.0.0) for statistical analysis. Data were reported as means
(standard deviations) unless otherwise indicated.
Results
Between 11 and 29 March 2003 SARS was diagnosed in 160 patients
at the
Prince of Wales Hospital. We excluded three patients
with a history of
pancytopenia due to myelodysplastic syndrome
(n=2) and systemic lupus
erythematosus (n=1) from our analysis.
We documented seroconversion or a
greater than fourfold increase
in antibody titre between acute and
convalescence sera in 138
patients. Serum samples were not available in the
remaining
19 convalescing patients, but six of them tested positive for
coronavirus on culture. The study included 64 male and 93 female
patients, all
ethnic Chinese. Their mean age was 38.5 years
(range 20-83 years). The median
duration of follow up was 26
days (range 4-38 days). All patients received
broad spectrum
antibiotics and a combination of ribavirin and prednisolone
0.5
mg/kg/day as empirical treatment. Intravenous methylprednisolone
at high
dosage was used in patients with respiratory distress
or progressive
consolidations on their chest radiograph.
White blood cells
Transient leucopenia (leucocyte count < 4x109/l) was
found in 100 (64%) of patients during their first week of illness. Ninety six
patients (61%) developed leucocytosis (leucocyte count >
11x109/l), mostly during the second and third week of
illness.
Neutrophils
Four patients (2.5%) developed transient neutropenia (absolute neutrophil
count < 0.5x109/l) lasting for one to two days. We noted
neutrophilia (absolute neutrophil count > 7.5x109/l) in
129 (82%) of patients. Univariate analysis showed that neutrophilia at any
time was associated with a higher incidence of bacterial infections,
documented by microbiological cultures (P=0.017). Most of these infections
were hospital acquired pneumonia or line sepsis.
Lymphocytes
Lymphopenia (absolute lymphocyte count < 1000/mm3) was noted
in 153 (98% of patients) during their course of illness. Most patients had a
normal lymphocyte count at the onset of disease. Progressive lymphopenia
occurred early in the course of illness and reached its lowest point in the
second week in most cases. The lymphocyte count commonly recovered in the
third week, but about 30% (14 of 47) of patients remained lymphopenic at the
fifth week of SARS (fig 1).

View larger version (28K):
[in this window]
[in a new window]
|
Fig 1 Proportion of patients with absolute lymphopenia during the course of SARS.
The number in parentheses indicates the number of observations available at
each of the different time points
|
|
We analysed subsets of peripheral blood lymphocytes in 31 patients. The
mean CD4 and CD8 cell counts at presentation were 286.7 (SD 142.2) cells/µl
(normal range 410 to 1590 cells/µl) and 242.2 (SD 130.8) cells/µl
(normal range 62 to 559 cells/µl) respectively. Most patients had reduced
CD4 and CD8 cell counts during the early phase of illness, which reached a
trough on days 5 to 14 and recovered gradually afterwards
(fig 2). Five patients had an
initial rise of CD4 and CD8 cell counts during the first week of illness,
followed by a fall of both cell counts. The ratio of CD4 to CD8 cells remained
in the normal range. The mean B lymphocyte count in peripheral blood at
presentation was 151.3 (SD 73.2) per µl (normal range 90-660 cells/µl)
and remained stable.


View larger version (62K):
[in this window]
[in a new window]
|
Fig 2 Individual plots of CD4 and CD8 lymphocyte subsets in peripheral blood
against day of illness in 31 patients
|
|
Platelet count
Eighty seven patients (55%) developed thrombocytopenia (platelet count <
140 000/mm3) during the course of their illness. Most of them had
mild thrombocytopenia, and only three (2%) patients had a platelet count below
50 000/mm3 (fig 1).
Most patients' platelet count was normal at the onset of illness. Progressive
thrombocytopenia occurred and reached a low point at the end of the first
week. Thrombocytopenia was self limiting and resolved by the fourth week of
illness. No patient had major bleeding or required platelet transfusion.
Reactive thrombocytosis (platelet count ≥ 400 000/mm3) was
noted in 77 (49%) of patients (fig
3). The platelet count peaked on a median of day 17 of illness
(range day 6 to 31). Only one patient had a platelet count above 1 000
000/mm3, and she had no evidence of thromboembolism.

View larger version (32K):
[in this window]
[in a new window]
|
Fig 3 Proportion of patients with various platelet counts during the course of
SARS. The number in parentheses indicates the number of observations available
at each of the different time points
|
|
Haemoglobin
Except for four patients with haemoglobin counts ranging from 95 g/l to 105
g/l due to
thalassaemia trait (n=1), iron deficiency (n=2), and
alcoholic liver disease (n=1), all patients had normal haemoglobin counts at
presentation. After two weeks of taking ribavirin at a dosage of 400 mg every
8 hours intravenously or 1200 mg thrice daily orally, the haemoglobin count
dropped by more than 20 g/l from baseline in 95 patients (61%) and by more
than 30 g/l in 44 patients (28%). We found no evidence of major bleeding, and
no patient needed a transfusion or withdrawal of ribavirin. Of the 95 patients
with a haemoglobin drop of more than 20 g/l, 57 showed evidence of haemolysis
(rise of bilirubin > 20 µmol/l or reticulocyte count > 1%, or both).
We found no evidence of an immune related cause of haemolysis. Haemoglobin
concentrations recovered gradually after treatment with ribavirin was stopped
in all patients.
Clotting profile
We excluded from the analysis four patients with mechanical heart valve
prostheses (n=3) and atrial fibrillation (n=1) who were taking long term
warfarin. Of the remaining 153 patients, 96 (63%) had isolated prolonged
activated partial thromboplastin time (> 40 seconds) and normal prothrombin
time during their course of illness (fig
4). The prolonged activated partial thromboplastin time ranged
from 40.1 seconds to 68.1 seconds and occurred mainly in the first two weeks
of illness. We found no evidence of venous thromboembolism or other
coagulation abnormalities such as the presence of the anticardiolipin antibody
or raised D-dimer concentrations. No patient required plasma
transfusion or treatment with clotting factors. The abnormal clotting profile
was self limiting, and all patients showed a normal activated partial
thromboplastin time at week 4. Fifty two patients (34%) had normal clotting
profiles throughout the course of their illness.

View larger version (22K):
[in this window]
[in a new window]
|
Fig 4 Proportion of patients with abnormal activated partial thromboplastin time
during the course of SARS. The number in parentheses indicates the number of
observations available at each of the different time points
|
|
Four patients (2.5%) developed frank disseminated intravascular coagulation
with markedly prolonged prothrombin time, activated partial thromboplastin
time, thrombocytopenia, and raised D-dimer concentrations. One
patient had respiratory failure and needed mechanical ventilation at the time
of analysis. The other three patients died of severe respiratory distress with
multiorgan failure, and two of them had superimposed bacterial infections.
Factors associated with admission to intensive care and death
Univariate analysis showed that the development of thrombocytopenia and
high absolute neutrophil count at presentation were associated with admission
to intensive or death (table).
In the multivariate analysis, advanced age and a high concentration of lactate
dehydrogenase at presentation were independent predictors of adverse outcomes.
In the subgroup of patients whose lymphocyte subsets were analysed, low CD4
and CD8 counts at presentation were associated with adverse outcomes.
View this table:
[in this window]
[in a new window]
|
Univariate analysis of clinical and laboratory variables associated with
the composite outcome of intensive care or death. Values are numbers (%) of
patients with respective abnormalities unless otherwise indicated
|
|
Haemato-lymphoid pathology
At autopsy the haemato-lymphoid organs of the four patients who died showed
no enlarged lymph nodes in peripheral soft tissues or other body parts. We
noted no reactive lymphoid hyperplasia or T zone reaction. The splenic white
pulps of all cases appeared atrophic with lymphoid depletion, and the red pulp
was congested (fig 5). Bone
marrow appeared active with presence of three lineages. We noted no features
of hypoplastic marrow or reactive haemophagocytic syndrome in any of the
patients. The pulmonary pathology was dominated by diffuse alveolar damage,
and the lymphoid infiltrate was sparse. Viral isolation, in particular for
coronavirus, showed negative results in the splenic, lymph node, and bone
marrow tissues.
Discussion
Abnormal haematological variables were common among patients
with the new
respiratory illness known as SARS, which has had
a large impact
worldwide.
5
Lymphopenia and the depletion of
T lymphocyte subsets may be associated with
disease activity.
Studies of its effect on various body systems are crucial to the
understanding of this disease. Lymphopenia was the most common finding in our
study in a cohort of 157 patients with SARS. Postmortem findings showed
lymphopenia in various lymphoid organs. We found no features of bone marrow
failure or reactive haemophagocytic syndrome. The inflammatory exudates in the
lungs showed scanty lymphocytes. In those patients whose lymphocyte subset was
analysed, both mean CD4 and CD8 cell counts were low at presentation and fell
further during the early course of illness. The patients in this subgroup were
young (median age 27 years, range 21 to 58 years) and had no comorbidity. We
believe that the low CD4 and CD8 cell counts reflected the severity of
infection due to the SARS virus and are therefore good markers of disease
activity. Depletion of lymphocytes may be secondary to the direct effect of
the virus on the lymphocytes or the effect of various
cytokines.6
7 Neutrophilia was also
common among patients with SARS and might be related to treatment with
corticosteroids, but our results implied that full sepsis work up and
empirical broad spectrum antibiotics should be considered in patients with
neutrophilia.
Thrombocytopenia followed by reactive thrombocytosis was another common
finding in our study. Thrombocytopenia has been reported in a variety of viral
infections.813
It may be caused by an immune mechanism or a direct effect of viruses on
megakaryocytes or
platelets.13
Megakaryocytes are capable of harbouring a variety of viruses, although the
mechanism of viral entry into megakaryocytes is not well understood.
Dysmorphic megakaryocytes containing inclusion bodies, vacuoles, degenerating
nuclei, or showing naked nuclei may be seen in infected
marrow.14 In most
patients we found no evidence of disseminated intravascular coagulation. The
postmortem findings of active bone marrow with normal megakaryoctes in
patients with thrombocytopenia favour an immune cause of thrombocytopenia.
| What is already known on this topic
Severe acute respiratory syndrome (SARS) is an emerging infection that is
spreading worldwide
The haematological features of this disease have not been described in
detail elsewhere
Previous studies have indicated that patients with SARS may develop
lymphopenia and thrombocytopenia, but the significance of these findings is
uncertain
What this study adds
Lymphopenia was common among patients with SARS. It was also found in
various lymphoid tissues on postmortem examination and may be a marker of
disease activity
Both CD4 and CD8 counts decreased during the early course of SARS. Low CD4
and CD8 lymphocyte counts at presentation were associated with adverse
outcomes
Leucocytosis with neutrophilia, thrombocytopenia, and isolated prolonged
activated partial thromboplastin time were common in patients with SARS
| |
A major side effect of ribavirin is reversible haemolytic
anaemia.15
16 About 60% of our
patients who received ribavirin experienced a drop of haemoglobin of more than
20 g/l. Despite this high drop, ribavirin was well tolerated and none of the
patients needed withdrawal of treatment or transfusion. The development of
anaemia may be a cause for concern. None the less haemolysis was transient,
and haemoglobin counts improved after treatment with ribavirin had been
completed in all cases. Careful monitoring of haemoglobin is advisable for
patients who receive ribavirin.
Conclusions
Lymphopenia, in particular T lymphopenia, was common among patients
with
SARS in our study. A notable drop in CD4 and CD8 lymphocyte
counts occurred
early in the course of the syndrome and was
associated with adverse outcomes.
Thrombocytopenia, neutrophilia,
and transient prolonged activated partial
thromboplastin time
were other common findings. Further studies to evaluate
the
mechanisms of these manifestations may help us to understand
this
disease.
We thank the Haematology Division of the Department of Anatomical and
Cellular Pathology for their full support in the laboratory
investigations.
Contributors: JJYS is guarantor and was responsible for patient management
and coordinated the study. RSMW and GC were responsible for the study design,
analysis, and writing of the paper. AW, NL, and DSH were responsible for
patient management and data collection. KFT was responsible for postmortem
examinations. MHLN, CWKL, and CKW were responsible for the haematological
laboratory tests. PKSC and JST were responsible for the virological studies.
LMY was responsible for the statistical analysis.
Funding: None.
Competing interests: None declared.
Ethical approval: The study was approved by the ethics committee of the
Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese
University of Hong Kong.
References
- Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. A major
outbreak of severe acute respiratory syndrome in Hong Kong. N Engl
J Med 2003;348:
1986-94.[Abstract/Free Full Text]
- Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et
al. A novel coronavirus associated with severe acute respiratory syndrome.
N Engl J Med
2003;348:
1953-66.[Abstract/Free Full Text]
- Peiris J, Lai S, Poon L, Guan Y, Yam L, Lim W, et al. Coronavirus
as a possible cause of severe acute respiratory syndrome.
Lancet 2003;361:
1319-25.[CrossRef][Web of Science][Medline]
- Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K, et
al. Identification of severe acute respiratory syndrome in Canada.
N Engl J Med
2003;348:
1995-2005.[Abstract/Free Full Text]
- Outbreak of severe acute respiratory syndrome--worldwide, 2003.
MMWR Morb Mortal Wkly Rep
2003;52:
226-8.[Medline]
- Maury CP, Lahdevirta J. Correlation of serum cytokine levels with
haematological abnormalities in human immunodeficiency virus infection.
J Intern Med
1990;227:
253-7.[Web of Science][Medline]
- Van Campen H, Easterday BC, Hinshaw VS. Destruction of lymphocytes
by a virulent avian influenza A virus. J Gen Virol
1989;70(Pt 2):
467-72.[Abstract/Free Full Text]
- Eisenberg MJ, Kaplan B. Cytomegalovirus-induced thrombocytopenia in
an immunocompetent adult. West J Med
1993;158:
525-6.[Web of Science][Medline]
- Ninomiya N, Maeda T, Matsuda I. Thrombocytopenic purpura occurring
during the early phase of a mumps infection. Helv Paediatr
Acta 1977;32:
87-9.[Web of Science][Medline]
- Oski FA, Naiman JL. Effect of live measles vaccine on the platelet
count. N Engl J Med
1966;275:
352-6.[Web of Science][Medline]
- Van Spronsen DJ, Breed WP. Cytomegalovirus-induced thrombocytopenia
and haemolysis in an immunocompetent adult. Br J
Haematol 1996;92:
218-20.[CrossRef][Web of Science][Medline]
- Ballem PJ, Belzberg A, Devine DV, Lyster D, Spruston B, Chambers H,
et al. Kinetic studies of the mechanism of thrombocytopenia in patients with
human immunodeficiency virus infection. N Engl J Med
1992;327:
1779-84.[Abstract]
- Zucker-Franklin D. The effect of viral infections on platelets and
megakaryocytes. Semin Hematol
1994;31:
329-37.[Web of Science][Medline]
- Chesney PJ, Taher A, Gilbert EM, Shahidi NT. Intranuclear
inclusions in megakaryocytes in congenital cytomegalovirus infection.
J Pediatr 1978;92:
957-8.[CrossRef][Web of Science][Medline]
- McCromick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM,
et al. Lassa fever. Effective therapy with ribavirin. N Engl J
Med 1986;314:
20-6.[Abstract]
- Roberts RB, Laskin OL, Laurence J, Scavuzzo D, Murray HW, Kim YT,
et al. Ribavirin pharmacodynamics in high-risk patients for acquired
immunodeficiency syndrome. Clin Pharmacol Ther
1987;42:
365-73.[Web of Science][Medline]
(Accepted May 23, 2003)

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?
Relevant Articles
-
Real time assay of Aspergillus should be used in SARS patients receiving corticosteroids
- Ya Ping Wu, Ran Wei, and Jan Verhoef
BMJ 2003 327: 1405.
[Extract]
[Full Text]
-
SARS: understanding the coronavirus: Apoptosis may explain lymphopenia of SARS
- Roddy O'Donnell, Robert C Tasker, and Michael F E Roe
BMJ 2003 327: 620.
[Extract]
[Full Text]
-
Haematological changes signal outcome in SARS patients
BMJ 2003 326: 0.
[Full Text]
This article has been cited by other articles:
-
Yoshikawa, N., Yoshikawa, T., Hill, T., Huang, C., Watts, D. M., Makino, S., Milligan, G., Chan, T., Peters, C. J., Tseng, C.-T. K.
(2009). Differential Virological and Immunological Outcome of Severe Acute Respiratory Syndrome Coronavirus Infection in Susceptible and Resistant Transgenic Mice Expressing Human Angiotensin-Converting Enzyme 2. J. Virol.
83: 5451-5465
[Abstract]
[Full text]
-
Bitnun, A., Read, S., Tellier, R., Petric, M., Richardson, S. E.
(2009). Severe Acute Respiratory Syndrome-Associated Coronavirus Infection in Toronto Children: A Second Look. Pediatrics
123: 97-101
[Abstract]
[Full text]
-
Bradfute, S. B., Warfield, K. L., Bavari, S.
(2008). Functional CD8+ T Cell Responses in Lethal Ebola Virus Infection. J. Immunol.
180: 4058-4066
[Abstract]
[Full text]
-
Cameron, M. J., Ran, L., Xu, L., Danesh, A., Bermejo-Martin, J. F., Cameron, C. M., Muller, M. P., Gold, W. L., Richardson, S. E., Poutanen, S. M., Willey, B. M., DeVries, M. E., Fang, Y., Seneviratne, C., Bosinger, S. E., Persad, D., Wilkinson, P., Greller, L. D., Somogyi, R., Humar, A., Keshavjee, S., Louie, M., Loeb, M. B., Brunton, J., McGeer, A. J., the Canadian SARS Research Network, , Kelvin, D. J.
(2007). Interferon-Mediated Immunopathological Events Are Associated with Atypical Innate and Adaptive Immune Responses in Patients with Severe Acute Respiratory Syndrome. J. Virol.
81: 8692-8706
[Abstract]
[Full text]
-
Zhao, G.-p.
(2007). SARS molecular epidemiology: a Chinese fairy tale of controlling an emerging zoonotic disease in the genomics era. Phil Trans R Soc B
362: 1063-1081
[Abstract]
[Full text]
-
Gu, J., Korteweg, C.
(2007). Pathology and Pathogenesis of Severe Acute Respiratory Syndrome. Am. J. Pathol.
170: 1136-1147
[Abstract]
[Full text]
-
Zhan, J., Deng, R., Tang, J., Zhang, B., Tang, Y., Wang, J. K., Li, F., Anderson, V. M., McNutt, M. A., Gu, J.
(2006). The spleen as a target in severe acute respiratory syndrome. FASEB J.
20: 2321-2328
[Abstract]
[Full text]
-
Bahl, K., Kim, S.-K., Calcagno, C., Ghersi, D., Puzone, R., Celada, F., Selin, L. K., Welsh, R. M.
(2006). IFN-Induced Attrition of CD8 T Cells in the Presence or Absence of Cognate Antigen during the Early Stages of Viral Infections. J. Immunol.
176: 4284-4295
[Abstract]
[Full text]
-
Yu, C-M, Wong, R S-M, Wu, E B, Kong, S-L, Wong, J, Yip, G W-K, Soo, Y O Y, Chiu, M L S, Chan, Y-S, Hui, D, Lee, N, Wu, A, Leung, C-B, Sung, J J-Y
(2006). Cardiovascular complications of severe acute respiratory syndrome. Postgrad. Med. J.
82: 140-144
[Abstract]
[Full text]
-
Kopecky-Bromberg, S. A., Martinez-Sobrido, L., Palese, P.
(2006). 7a Protein of Severe Acute Respiratory Syndrome Coronavirus Inhibits Cellular Protein Synthesis and Activates p38 Mitogen-Activated Protein Kinase. J. Virol.
80: 785-793
[Abstract]
[Full text]
-
Weiss, S. R., Navas-Martin, S.
(2005). Coronavirus Pathogenesis and the Emerging Pathogen Severe Acute Respiratory Syndrome Coronavirus. Microbiol. Mol. Biol. Rev.
69: 635-664
[Abstract]
[Full text]
-
Hung, V.W.Y., Qin, L., Cheung, C.S.K., Lam, T.P., Ng, B.K.W., Tse, Y.K., Guo, X., Lee, K.M., Cheng, J.C.Y.
(2005). Osteopenia: A New Prognostic Factor of Curve Progression in Adolescent Idiopathic Scoliosis. JBJS
87: 2709-2716
[Abstract]
[Full text]
-
Antonio, G. E., Ooi, C. G. C., Wong, K. T., Tsui, E. L. H., Wong, J. S. W., Sy, A. N. L., Hui, J. Y. H., Chan, C. Y., Huang, H. Y. H., Chan, Y. F., Wong, T. P., Leong, L. L. Y., Chan, J. C. K., Ahuja, A. T.
(2005). Radiographic-Clinical Correlation in Severe Acute Respiratory Syndrome: Study of 1373 Patients in Hong Kong. Radiology
237: 1081-1090
[Abstract]
[Full text]
-
Law, H. K. W., Cheung, C. Y., Ng, H. Y., Sia, S. F., Chan, Y. O., Luk, W., Nicholls, J. M., Peiris, J. S. M., Lau, Y. L.
(2005). Chemokine up-regulation in SARS-coronavirus-infected, monocyte-derived human dendritic cells. Blood
106: 2366-2374
[Abstract]
[Full text]
-
Tan, Y.-J., Tham, P.-Y., Chan, D. Z. L., Chou, C.-F., Shen, S., Fielding, B. C., Tan, T. H. P., Lim, S. G., Hong, W.
(2005). The Severe Acute Respiratory Syndrome Coronavirus 3a Protein Up-Regulates Expression of Fibrinogen in Lung Epithelial Cells. J. Virol.
79: 10083-10087
[Abstract]
[Full text]
-
Liang, Y., Wan, Y., Qiu, L.-w., Zhou, J., Ni, B., Guo, B., Zou, Q., Zou, L., Zhou, W., Jia, Z., Che, X.-y., Wu, Y.
(2005). Comprehensive Antibody Epitope Mapping of the Nucleocapsid Protein of Severe Acute Respiratory Syndrome (SARS) Coronavirus: Insight into the Humoral Immunity of SARS. Clin. Chem.
51: 1382-1396
[Abstract]
[Full text]
-
Cheng, F W T, Ng, P C, Chiu, W K, Chu, W C W, Li, A M, Lo, K L, Hon, E K L, Nelson, E A S, Leung, T F, Ng, W H, Wong, E, Ip, P, Fok, T F
(2005). A case-control study of SARS versus community acquired pneumonia. Arch. Dis. Child.
90: 747-749
[Abstract]
[Full text]
-
Tseng, C.-T. K., Perrone, L. A., Zhu, H., Makino, S., Peters, C. J.
(2005). Severe Acute Respiratory Syndrome and the Innate Immune Responses: Modulation of Effector Cell Function without Productive Infection. J. Immunol.
174: 7977-7985
[Abstract]
[Full text]
-
Ng, K H L, Wu, A K L, Cheng, V C C, Tang, B S F, Chan, C Y, Yung, C Y, Luk, S H, Lee, T W, Chow, L, Yuen, K Y
(2005). Pulmonary artery thrombosis in a patient with severe acute respiratory syndrome. Postgrad. Med. J.
81: e3-e3
[Abstract]
[Full text]
-
Tang, B. S. F., Chan, K.-h., Cheng, V. C. C., Woo, P. C. Y., Lau, S. K. P., Lam, C. C. K., Chan, T.-l., Wu, A. K. L., Hung, I. F. N., Leung, S.-y., Yuen, K.-y.
(2005). Comparative Host Gene Transcription by Microarray Analysis Early after Infection of the Huh7 Cell Line by Severe Acute Respiratory Syndrome Coronavirus and Human Coronavirus 229E. J. Virol.
79: 6180-6193
[Abstract]
[Full text]
-
Jiang, Y., Xu, J., Zhou, C., Wu, Z., Zhong, S., Liu, J., Luo, W., Chen, T., Qin, Q., Deng, P.
(2005). Characterization of Cytokine/Chemokine Profiles of Severe Acute Respiratory Syndrome. Am. J. Respir. Crit. Care Med.
171: 850-857
[Abstract]
[Full text]
-
Marrie, T. J., Wu, L.
(2005). Factors Influencing In-hospital Mortality in Community-Acquired Pneumonia: A Prospective Study of Patients Not Initially Admitted to the ICU. Chest
127: 1260-1270
[Abstract]
[Full text]
-
de Groot-Mijnes, J. D. F., van Dun, J. M., van der Most, R. G., de Groot, R. J.
(2005). Natural History of a Recurrent Feline Coronavirus Infection and the Role of Cellular Immunity in Survival and Disease. J. Virol.
79: 1036-1044
[Abstract]
[Full text]
-
Yip, T. T.C., Chan, J. W.M., Cho, W. C.S., Yip, T.-T., Wang, Z., Kwan, T.-L., Law, S. C.K., Tsang, D. N.C., Chan, J. K.C., Lee, K.-C., Cheng, W.-W., Ma, V. W.S., Yip, C., Lim, C. K.P., Ngan, R. K.C., Au, J. S.K., Chan, A., Lim, W. W.L., and Queen Elizabeth Hospital/Hong Kong Government,
(2005). Protein Chip Array Profiling Analysis in Patients with Severe Acute Respiratory Syndrome Identified Serum Amyloid A Protein as a Biomarker Potentially Useful in Monitoring the Extent of Pneumonia. Clin. Chem.
51: 47-55
[Abstract]
[Full text]
-
Chen, J.-H., Chang, Y.-W., Yao, C.-W., Chiueh, T.-S., Huang, S.-C., Chien, K.-Y., Chen, A., Chang, F.-Y., Wong, C.-H., Chen, Y.-J.
(2004). Plasma proteome of severe acute respiratory syndrome analyzed by two-dimensional gel electrophoresis and mass spectrometry. Proc. Natl. Acad. Sci. USA
101: 17039-17044
[Abstract]
[Full text]
-
Chu, C.-M., Poon, L. L.M., Cheng, V. C.C., Chan, K.-S., Hung, I. F.N., Wong, M. M.L., Chan, K.-H., Leung, W.-S., Tang, B. S.F., Chan, V. L., Ng, W.-L., Sim, T.-C., Ng, P.-W., Law, K.-I., Tse, D. M.W., Peiris, J. S.M., Yuen, K.-Y.
(2004). Initial viral load and the outcomes of SARS. CMAJ
171: 1349-1352
[Abstract]
[Full text]
-
Chiang, C.-H., Shih, J.-F., Su, W.-J., Perng, R.-P.
(2004). Eight-Month Prospective Study of 14 Patients With Hospital-Acquired Severe Acute Respiratory Syndrome. Mayo Clin Proc.
79: 1372-1379
[Abstract]
-
Wyllie, D H, Bowler, I C J W, Peto, T E A
(2004). Relation between lymphopenia and bacteraemia in UK adults with medical emergencies. J. Clin. Pathol.
57: 950-955
[Abstract]
[Full text]
-
Zhang, Y., Li, J., Zhan, Y., Wu, L., Yu, X., Zhang, W., Ye, L., Xu, S., Sun, R., Wang, Y., Lou, J.
(2004). Analysis of Serum Cytokines in Patients with Severe Acute Respiratory Syndrome. Infect. Immun.
72: 4410-4415
[Abstract]
[Full text]
-
Parashar, U. D, Anderson, L. J
(2004). Severe acute respiratory syndrome: review and lessons of the 2003 outbreak. Int J Epidemiol
33: 628-634
[Full text]
-
Mok, C C, Ying, K Y
(2004). Lupus pneumonitis or severe acute respiratory syndrome?. Lupus
13: 549-553
[Abstract]
-
Wang, H., Mao, Y., Ju, L., Zhang, J., Liu, Z., Zhou, X., Li, Q., Wang, Y., Kim, S., Zhang, L.
(2004). Detection and Monitoring of SARS Coronavirus in the Plasma and Peripheral Blood Lymphocytes of Patients with Severe Acute Respiratory Syndrome. Clin. Chem.
50: 1237-1240
[Full text]
-
Kwan, B. C.-H., Leung, C.-B., Szeto, C.-C., Wong, V. W.-S., Cheng, Y.-L., Yu, A. W.-Y., Li, P. K.-T.
(2004). Severe Acute Respiratory Syndrome in Dialysis Patients. J. Am. Soc. Nephrol.
15: 1883-1888
[Abstract]
[Full text]
-
Hui, D S C, Chan, M C H, Wu, A K, Ng, P C
(2004). Severe acute respiratory syndrome (SARS): epidemiology and clinical features. Postgrad. Med. J.
80: 373-381
[Abstract]
[Full text]
-
Wang, B., Chen, H., Jiang, X., Zhang, M., Wan, T., Li, N., Zhou, X., Wu, Y., Yang, F., Yu, Y., Wang, X., Yang, R., Cao, X.
(2004). Identification of an HLA-A*0201-restricted CD8+ T-cell epitope SSp-1 of SARS-CoV spike protein. Blood
104: 200-206
[Abstract]
[Full text]
-
Hofmann, H., Hattermann, K., Marzi, A., Gramberg, T., Geier, M., Krumbiegel, M., Kuate, S., Uberla, K., Niedrig, M., Pohlmann, S.
(2004). S Protein of Severe Acute Respiratory Syndrome-Associated Coronavirus Mediates Entry into Hepatoma Cell Lines and Is Targeted by Neutralizing Antibodies in Infected Patients. J. Virol.
78: 6134-6142
[Abstract]
[Full text]
-
Chu, C M, Cheng, V C C, Hung, I F N, Wong, M M L, Chan, K H, Chan, K S, Kao, R Y T, Poon, L L M, Wong, C L P, Guan, Y, Peiris, J S M, Yuen, K Y
(2004). Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax
59: 252-256
[Abstract]
[Full text]
-
Peiris, J. S.M., Yuen, K. Y., Osterhaus, A. D.M.E., Stohr, K.
(2003). The Severe Acute Respiratory Syndrome. NEJM
349: 2431-2441
[Full text]
-
Wu, Y. P., Wei, R., Verhoef, J.
(2003). Real time assay of Aspergillus should be used in SARS patients receiving corticosteroids. BMJ
327: 1405-1405
[Full text]
-
Choi, K. W., Chau, T. N., Tsang, O., Tso, E., Chiu, M. C., Tong, W. L., Lee, P. O., Ng, T. K., Ng, W. F., Lee, K. C., Lam, W., Yu, W. C., Lai, J. Y., Lai, S. T., the Princess Margaret Hospital SARS Study Group*,
(2003). Outcomes and Prognostic Factors in 267 Patients with Severe Acute Respiratory Syndrome in Hong Kong. ANN INTERN MED
139: 715-723
[Abstract]
[Full text]
-
O'Donnell, R., Tasker, R. C, Roe, M. F E
(2003). SARS: understanding the coronavirus: Apoptosis may explain lymphopenia of SARS. BMJ
327: 620-620
[Full text]
Rapid Responses:
Read all Rapid Responses
- A Mechanism to Explain the T lymphopenia
- Trevor G Marshall, et al.
bmj.com, 20 Jun 2003
[Full text]
- Lymphopenia in SARS - Apoptosis?
- D. Roddy O'Donnell, et al.
bmj.com, 24 Jun 2003
[Full text]
- PCR and GM-ELISA diagnosis of aspergillosis for SARS patients received corticosteroids treatment
- Ya Ping Wu, et al.
bmj.com, 3 Oct 2003
[Full text]